CAR-T / CAR-NK And Adoptive Cell Therapies Market Size, Trends, Share, Growth, and Opportunity Forecast, 2025 – 2032 Global Industry Analysis By Type (Autologous CAR-T, Allogeneic CAR-NK, TCR-Engineered Cells, Tumor-Infiltrating Lymphocytes (TILs), and Others), By Application (Hematologic Malignancies, Solid Tumors, Combination Regimens, Autoimmune Indications, and Others), By End-User (Academic & Research Hospitals, Specialty Therapy Centers, Commercial Cell Therapy CDMOs, Biopharmaceutical Companies, and Others), and By Geography (North America, Europe, Asia Pacific, South America, and Middle East & Africa)

By Type

·         Autologous CAR-T
·         Allogeneic CAR-NK
·         TCR-Engineered Cells
·         Tumor-Infiltrating Lymphocytes (TILs)
·         Others

By Application

·         Hematologic Malignancies
·         Solid Tumors
·         Combination Regimens
·         Autoimmune Indications
·         Others

By End-User

·         Academic & Research Hospitals
·         Specialty Therapy Centers
·         Commercial Cell Therapy CDMOs
·         Biopharmaceutical Companies
·         Others

Companies Profiled

·         Novartis AG
·         Gilead Sciences (Kite Pharma)
·         Bristol Myers Squibb
·         Johnson & Johnson (Janssen Biotech)
·         Fate Therapeutics
·         Nkarta Therapeutics
·         Allogene Therapeutics
·         Cellectis
·         Autolus Therapeutics
·         Legend Biotech
·         Adaptimmune Therapeutics